Clinical Research Studies
SPECIALIZING IN NOVEL AND INNOVATIVE RESEARCH APPROACHES FOR ALL TYPES OF CLINICAL DEPRESSION
***Due to current Covid-19 regulations, some studies are currently enrolling via televisits. We will be reviewing new applicants and enrolling when permitted. Please be aware that response times may be greater than usual during this time. ***
Augmentation versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD)
If you are between the ages of 18 and 80, currently depressed and have a history of trying at least one antidepressant medication you may be eligible.
This study involves comparing three treatment arms:
1. Adding Abilify® to current antidepressant medication
2. Switching your current antidepressant medication to Effexor® Extended Release (or Cymbalta®)
These two treatments are approved by the FDA to treat TRD. If enrolled, this study involves 8 virtual visits over 12 weeks.
Participants will receive compensation for their time.
If you are currently taking an antidepressant medication that is only partially helping your depression, please fill out our online survey, call (650) 723-8330 or email email@example.com.
For further details, please see the following link: https://clinicaltrials.gov/ct2/show/NCT02977299
Opiate Suicide Study in Patients with Major Depression
We are doing this study to determine if suicidal thoughts are lessened after an infusion of ketamine followed by 4 weeks of a medication called buprenorphine. Participants for this research will be currently experiencing depression and will have not responded to treatment with antidepressants or have an intolerance to these types of medicines. Recent studies have shown a single infusion of ketamine to reduce suicidal ideation within 24 hours and to last for at least one week. We would like to determine if a single infusion of ketamine followed by 4 weeks of low dose burprenorphine produces longer lasting anti-suicidal effects than does ketamine followed by placebo.
This research study is expected to take approximately 2 years to complete with at least 6 weeks of active participation by each participant. During this time, participants will make 10 study visits to Stanford University, including an 8-hour infusion visit.
Under the close supervision and monitoring by the study clinicians, eligible subjects will receive a single infusion of ketamine 0.5mg/kg followed by oral buprenorphine or placebo for 4 weeks.
This research study will use either Buprenorphine or a placebo, containing no drug, to study if the benefits experienced from Ketamine can be improved or last longer when buprenorphine is taken for 4 weeks.
For further details, please see the following link: https://clinicaltrials.gov/ct2/show/NCT04116528
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)
A randomized study to determine the optimal therapeutic dose of Psilocybin in Treatment Resistant Depression (TRD). The main purpose of this study is to test how well psilocybin works to lessen depressive symptoms.
We will do this by comparing the effect of a single dose of 10mg or 25mg of psilocybin with a lower dose of 1mg. Your depressive symptoms will be measured by a change in your score for a questionnaire that looks at your depressive symptoms.
Psilocybin is a controlled drug and a chemical compound found in some species of mushrooms. Recent studies have suggested that psilocybin may help in treating depression and we wish to investigate this further. Psilocybin works on the serotonin system in the brain which is linked to the regulation of mood. Current regulations do not allow psilocybin to be prescribed in the United States for treating depression, although it has been approved for use in this research study.
This research study is expected to take approximately 2 years to complete. We will ask you to make at least 12 study visits to Stanford University. On the day of the psilocybin session, you will arrive at the clinical center between 8am and 9am. You may require additional visits if you need a longer time to stop your antidepressant medication.
To find out if this study is a good fit for you, please fill out our online survey, call (650) 723-8330 or email firstname.lastname@example.org.
For further details, please see the following link: https://clinicaltrials.gov/ct2/show/NCT03775200
Other Clinical Trial Opportunities for Depression at Stanford Medicine
Current studies led by Dr. Nolan Willams Assistant Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology) at the Stanford University Medical Center and Director of the Stanford Brain Stimulation Lab
Studies not actively recruiting
- Identifying Biological Markers for Severe Depression
- Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
- A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment (Schatzberg)
- A Pilot study of Self-Defense Training in Women with Trauma (Keller)
Past Research Studies
- Double-Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD) (N. Williams)
- Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) (C. DeBattista)
- A Long-term Follow-Up Study for the Evaluation of Patients who have a Deep Brain Stimulation System for the Adjunctive Treatment of Major Depressive Disorder (C. DeBattista)
- A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD) and Having Had – Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic (C. DeBattista)
- Radiosurgical Neuromodulation for Refractory Depression (H.B. Solvason)
- A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants. (C. DeBattista)
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (C. DeBattista)
- A Randomized, Parallel-group, Sham-controlled, Multisite Study to Evaluate the Efficacy and Safety of the Neurostar® Transcranial Magnetic Stimulation Clinical Research System in Patients with Major Depressive Disorder (H.B. Solvason)
- An Open Label, Multisite Study to Evaluate the Efficacy and Safety of the Neurostar® Transcranial Magnetic Stimulation Clinical Research System in Patients with Major Depressive Disorder (H.B. Solvason)
- A Twelve Month, Open-Label, Safety Trial of Fliberanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder (C. DeBattista)
- A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 25 Milligrams Twice Daily and 50 Milligrams Once Daily and Twice Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in North America. (C. DeBattista)
- Ropinerole CR as an Adjunctive Agent in the Treatment of Major Depression (C. DeBattista)
- A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy in Subjects with Depression Treatment Failure. (C. DeBattista)
- Quantitative Characterization of Insulin Resistance in Patients with Bipolar Disorder Treated with Atypical Antipsychotic Medication: Effect of Treatment with an Oral Hypoglycemic Agent (H.B. Solvason)
- A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects with Major Depressive Disorder (C. DeBattista)
- A Double-Blind, Placebo-Controlled Study of Mifepristone in Patients with Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT) (H.B. Solvason)
- Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits following Unilateral ECT for the Treatment of a Severe Major Depressive Episode (H.B. Solvason)
- An 8-week, randomized, double blind, fixed dosage, placebo-controlled, parallel group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52 week, open-label extension (C. DeBattista)
- International Study to Predict Optimised Treatment in Depression. (C. DeBattista)
- Neurobiological and Cognitive Comparison of Psychotic Major Depression, Schizoaffective Disorder, Schizophrenia, and Non Psychotic Major Depression (J. Keller)